MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
BioLineRx Ltd. (NASDAQ: BLRX)*
Organization & Developments: BioLineRX
Parents
BioLineRx Ltd. (NASDAQ: BLRX)*
Children
*A team of experts in science and drug development, pharmacy and regulation, and IP work select the best candidates to advance them usually through at least a Phase 2 proof of concept in humans before seeking medium to large pharma
*The company's core competency is to identify, in-license, and develop the most promising drug candidates generated by Israel and global research organizations, universities, and small biotech start-ups.
2017: BioLine Rx Ltd. has partnerships with Genentech, Perrigo (NASDAQ:PRGO), Merck (NYSE:MRK), and Novartis (NYSE:NVS)
2017: BioLine Rx: This Under-The-Radar Biotech Stock Is A Strong Buy At $1 - BioLineRx Ltd. (NASDAQ:BLRX)
2017: BioLineRx - Undervalued With Significant Pipeline, Large Pharma Collaborations, And Strong Balance Sheet - BioLineRx Ltd. (NASDAQ:BLRX)
2017: Has licensing deal for a nonalcoholic steatohepatitis {NASH} candidate under a strategic collaboration with Novartis (NYSE:NVS).
2017: On January 17, 2017, BioLine Rx announced that it was initiating phase 2A trials for BL-8040 in collaboration with Merck and The University of Texas MD Anderson Cancer Center
2018: BioLine RX: This $1 Biotech Stock Offers A Superb Risk To Reward Ratio And Upside Catalysts For 2018 - Hawkinvest
2019: BioLineRx: With A Lot Of Cash In Hand And Undervalued_seekingalpha.com
2020: Biotech Analysis Central Preview Series: BioLineRX
2022: BioLineRx (BLRX) Investor Presentation - Slideshow_ seekingalpha.com
2023: BioLineRx: Still A Buy, With Some Questions_ seekingalpha.com
2023: BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges_ seekingalpha.com
2024: BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
2024: Flipping a biotech incubator into a commercial company
Jumps
*Key People: BioLineRX
Finance & Acquisition: BioLineRX